DCOY - Conference and earnings call announcements

CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at The Small Cap Showcase, taking place Thursday, October 1, 2026 in New York City. Mr. Pierce will deliver a corporate overview and participate in one-on-one meetings with investors during the conference. Details of the presentation are as follows: Date: Thursday, October 1, 2026Time: 11:30 a.m. ETLocation: New York, NYPresenter: Rick Pierce, Chief Executive Officer of Decoy Therapeu

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer Rick Pierce will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on June 11, 2026 in Canary Wharf, London. The half-day event brings together analysts, institutional in

CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp to Co-Present at Peptide-Based Therapeutics Summit; Advisor Dr. Bradley Pentelute to Deliver Opening RemarksCAMBRIDGE, Mass., April 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category of antivirals engineered to target shared viral mechanisms using its proprietary peptide conjugate platform, IMP3ACT™, today announced that members of its executive leadership will present across two leading peptide therapeutics conferences in Boston the week of Apri

Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billion-dollar antiviral marketsCompany to participate in Virtual Investor Closing Bell event to discuss pathforward today at 4:00 PM ET. Access the event hereCAMBRIDGE, Mass. and HOUSTON, April 9, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today highlighted a series of recent strategic, operational and scientific achievements that underscore accelerating momentum and a clear trajectory toward becoming a clinical

Live video webcast with Rick Pierce, Chief Executive Officer of Decoy Therapeutics, on Thursday, April 9th at 4:00 PM ETRegister for the event hereCAMBRIDGE, Mass. and HOUSTON, April 6, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, announced that Rick Pierce, Chief Executive Officer of Decoy, will participate in a Virtual Investor Closing Bell event on Thursday, April 9, 2026, at 4:00 PM ET.  As

– Live video webcast on Tuesday, February 10th at 1:20 PM EST CAMBRIDGE, Mass. and HOUSTON, Feb. 5, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the presentation, Rick Pierce, Chief Executive Officer of Decoy Therapeutics, will provide a brief corporate overview, highlighti